頸動脈·腎臟動脈支架市場:市場規模(各市場區隔)，佔有率，法規，償付，手藝，預測(～2033年)

頸動脈狹窄建議三種治療方法。這些包括藥物治療、血管內治療和動脈內膜切除術。

對於狹窄 (>70%) 且在過去 6 個月至 1 年內出現症狀的患者，建議進行動脈內膜切除術，而不是支架置入術。頸動脈狹窄50%以下的患者不建議使用。血管內治療是治療頸動脈狹窄的新選擇。血管內治療是一種微創治療，使用支架打開受影響的動脈。另一方面，RAS主要由兩種適應症引起：動脈粥狀硬化性腎動脈狹窄（ARAS）和腎纖維肌性發育不良（FMD）。

本報告提供全球頸動脈·腎臟動脈支架市場相關詳細考察，市場上競爭情形，SWOT分析，到2033年為止的市場預測，COVID-19影響，地區，各國的趨勢等資訊。

目錄

現在上市的頸動脈·腎臟動脈支架和競爭情形

• 主要的產業趨勢的洞察
• 頸動脈·腎臟動脈支架的各市場區隔整體市場收益和2015年～2033年的市場展望
• 各市場區隔的手藝總數，台數，平均銷售價格，市場價值相關詳細資料

世界，地區，各國洞察

• 頸動脈·腎臟動脈支架市場SWOT分析
• 頸動脈·腎臟動脈支架市場相關競爭動態的洞察和趨勢
• 各國醫療制度概要
• 各國償付政策
• 各國醫療技術相關法規狀況

Carotid and Renal Artery Stents Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.

The model discusses in detail the impact of COVID-19 on Carotid and Renal Artery Stents market for the year 2020 and beyond. Three types of therapies are recommended for carotid stenosis. These therapies include medication, endovascular intervention, and endarterectomy.

Endarterectomy is recommended over stenting to patients who are suffering from stenosis (>70%) and have had symptoms for the last six months to a year. It is not recommended to individuals with 50% or less stenosis in the carotid artery. Endovascular therapy is a new option available to treat carotid stenosis. Endovascular treatment is a minimally invasive procedure using a stent to open the artery in the affected area. Whereas, RAS is primarily caused by two indications, Atherosclerotic Renal Artery Stenosis (ARAS) and Renal Fibromuscular Dysplasia (FMD).

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Carotid and Renal Artery Stents and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Carotid and Renal Artery Stents market revenue by segment and market outlooks from 2015-2033.
• Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Carotid and Renal Artery Stents market.
• Competitive dynamics insights and trends provided for Carotid and Renal Artery Stents market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Cordis Corp, Boston Scientific Corp, Silk Road Medical Inc, Medtronic Plc, Terumo Corp, Cook Medical Inc, Biotronik SE & Co KG, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Carotid and Renal Artery Stents marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Carotid and Renal Artery Stents market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Carotid and Renal Artery Stents market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Carotid and Renal Artery Stents market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Carotid and Renal Artery Stents market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.